Yu Li
Welcome,         Profile    Billing    Logout  
 11 Trials 
6 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Li, Yu
BRUIN CLL-321, NCT04666038: Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
NCT06842199: Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

Recruiting
3
360
RoW
ICP-488 Tablets, ICP-488 Placebo
Beijing InnoCare Pharma Tech Co., Ltd.
Plaque Psoriasis Patients
05/26
02/27
TSL-TCM-QZKL-Ⅲ, NCT06068478: A Study to Evaluate Efficacy and Safety of Qingzhu Granules in the Treatment of Acute Gouty Arthritis

Recruiting
3
472
RoW
Qingzhu Granules, Qingzhu Granules Placebo
Tasly Pharmaceutical Group Co., Ltd
Gouty Arthritis
10/25
10/25
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting
3
152
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
05/26
05/28
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
ARC-10, NCT04736173 / 2020-003562-39: Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

Calendar Jan 2025 - Dec 2026: Data from ARC-10 trial for 1L PD-L1 NSCLC
Active, not recruiting
2
169
Europe, US, RoW
Domvanalimab, AB154, Zimberelimab, AB122, Carboplatin, Paclitaxel, Pemetrexed, Pembrolizumab
Arcus Biosciences, Inc., Gilead Sciences
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
05/27
05/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Li, Yu
BRUIN CLL-321, NCT04666038: Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
NCT06842199: Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

Recruiting
3
360
RoW
ICP-488 Tablets, ICP-488 Placebo
Beijing InnoCare Pharma Tech Co., Ltd.
Plaque Psoriasis Patients
05/26
02/27
TSL-TCM-QZKL-Ⅲ, NCT06068478: A Study to Evaluate Efficacy and Safety of Qingzhu Granules in the Treatment of Acute Gouty Arthritis

Recruiting
3
472
RoW
Qingzhu Granules, Qingzhu Granules Placebo
Tasly Pharmaceutical Group Co., Ltd
Gouty Arthritis
10/25
10/25
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting
3
152
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
05/26
05/28
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
ARC-10, NCT04736173 / 2020-003562-39: Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

Calendar Jan 2025 - Dec 2026: Data from ARC-10 trial for 1L PD-L1 NSCLC
Active, not recruiting
2
169
Europe, US, RoW
Domvanalimab, AB154, Zimberelimab, AB122, Carboplatin, Paclitaxel, Pemetrexed, Pembrolizumab
Arcus Biosciences, Inc., Gilead Sciences
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
05/27
05/27

Download Options